RPE65 and respiratory distress syndrome in premature infants: The FDA approval in 2017 of Luxturna, the first and only IRD gene therapy aimed at treating LCA2 caused by mutations in the RPE65 gene, inspired researchers’ enthusiasm for developing treatments for other IRDs.